Protara Therapeutics (TARA) Total Liabilities (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Total Liabilities data on file, last reported at $10.7 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 6.35% year-over-year to $10.7 million in Q1 2026; TTM through Mar 2026 was $10.7 million, a 6.35% increase from a year earlier, with the FY2025 full-year figure at $13.1 million, down 8.83% from the prior year.
• Total Liabilities for Q1 2026 stood at $10.7 million, down from $13.1 million in the prior quarter.
• Over the last five years, Total Liabilities for TARA reached as high as $14.3 million in Q4 2024 and fell as low as $9.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $11.0 million across 5 years, with a median of $10.7 million in 2026.
• Across the five-year window, Total Liabilities soared 110.43% in 2022 and retreated 16.4% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $11.2 million in 2022, then declined by 5.12% to $10.6 million in 2023, then soared by 34.68% to $14.3 million in 2024, then fell by 8.83% to $13.1 million in 2025, then dropped by 17.93% to $10.7 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $10.7 million in Q1 2026, $13.1 million in Q4 2025, and $12.3 million in Q3 2025.